geriatrРоссийский журнал гериатрической медициныRussian Journal of Geriatric Medicine2686-86362686-8709Сайт издателя10.37586/2686-8636-4-2024-335-341geriatr-391Research ArticleОБЗОРЫREVIEWSРоль липопротеина (а) в формировании аутовоспалительного статуса и актуальность данной проблемы в кардиогериатрииThe Impact of Lipoprotein (A) on Autoinflammation and its Significance in Cardiogeriatricshttps://orcid.org/0009-0001-1213-3287КоротковаЕ. В.KorotkovaE. V.

Короткова Елена Владимировна,

г. Санкт-Петербург.

ResearcherID: IAO-5719-2023

Korotkova Elena Vladimirovna, 

Saint Petersburg.

ResearcherID: IAO-5719-2023

jel.korotkova@gmail.comhttps://orcid.org/0009-0002-2847-6871ЗавьяловА. В.ZavyalovA. V.

Завьялов Андрей Васильевич,

г. Санкт-Петербург.

Zavyalov Andrew Vasil'evich,

Saint Petersburg.

andrewzavyalov2002@gmail.comhttps://orcid.org/0009-0009-4435-5755КоваленкоА. Ю.KovalenkoA. Yu.

Коваленко Ангелина Юрьевна,

г. Санкт-Петербург.

Kovalenko Angelina Yurievna,

Saint Petersburg.

13vitamortem13@gmail.comФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education “Academician I.P. Pavlov First St. Petersburg State Medical University” of the Ministry of Healthcare of Russian FederationRussian Federation20242012202404335341Copyright © Короткова Е.В., Завьялов А.В., Коваленко А.Ю., 20252025Короткова Е.В., Завьялов А.В., Коваленко А.Ю.Korotkova E.V., Zavyalov A.V., Kovalenko A.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.geriatr-news.com/jour/article/view/391

Липопротеин (а) (Лп(а)) в связи со своими структурными особенностями инициирует механизмы развития воспалительной реакции, состояния тромбофилии и атерогенеза. Важно обратить внимание на то, что в клинической практике нет рекомендаций по рутинному определению уровня липопротеина (а) в раннем возрасте, несмотря на актуальность данного параметра (в том числе длительность его изменения относительно нормы) в оценке сердечно-сосудистого риска и исходов у пациентов старшего возраста: даже при нормальных показателях липидограммы возможно уплотнение стенок артерий мышечно-эластического типа и образование атеросклеротических бляшек, при этом интенсивность данного процесса напрямую зависит от того, насколько сильно повышен уровень липопротеина (а), так как данный показатель генетически детерминирован.

Данная работа призвана оценить роль липопротеина (а) как фактора формирования низкоинтенсивного аутовоспалительного статуса, а также рассмотреть патогенетические особенности атеросклероза, обусловленного повышенным уровнем липопротеина (а) в плазме крови. Методологическим основанием исследования является критический и концептуальный анализ современных представлений о липопротеине (а) как об атерогенном факторе в научной литературе.

Lipoprotein (а) is able to initiate mechanisms of inflammation and create an atherogenic and thrombophilic condition due to its structural features. It is important to acknowledge that there are currently no standardized protocols for the regular monitoring of lipoprotein (а) levels in clinical settings, despite its relevance in assessing cardiovascular risk among older patients. Even in the absence of abnormal lipid profiles, there may still be thickening of the arterial walls and the formation of atherosclerotic plaque. The extent of atherogenicity, or plaque development, is directly linked to plasma levels of lipoprotein (а), which have a genetic basis.

This paper aims to review the role of lipoprotein (а) in low-grade inflammation and its pathogenic mechanisms in atherosclerosis, particularly in relation to elevated levels of this lipoprotein. The study will critically analyze the available literature on this topic to understand the potential role of lipoprotein (а) as a risk factor for atherosclerosis.

липопротеин (a)апопротеин (a)дислипидемииатеросклерозвоспалениеlipoprotein (a)apoprotein (a)dyslipidemiasatherosclerosisinflammationReferencesЕжов М.В., Кухарчук В.В., Сергиенко И.В., и др. Нарушения липидного обмена. Клинические рекомендации 2023 // Российский кардиологический журнал. 2023. Т. 28. № 5. С. 250–297. [Ezhov M.V., Kukharchuk V.V., Sergienko I.V. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250-297. (In Russ.)] https://doi.org/10.15829/1560-4071-2023-5471.Ежов М.В., Кухарчук В.В., Сергиенко И.В., и др. Нарушения липидного обмена. Клинические рекомендации 2023 // Российский кардиологический журнал. 2023. Т. 28. № 5. С. 250–297. [Ezhov M.V., Kukharchuk V.V., Sergienko I.V. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250-297. (In Russ.)] https://doi.org/10.15829/1560-4071-2023-5471.Waldeyer C., Makarova N., Zeller T., et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017;38(32):24902498. https://doi.org/10.1093/eurheartj/ehx166.Waldeyer C., Makarova N., Zeller T., et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017;38(32):24902498. https://doi.org/10.1093/eurheartj/ehx166.Coassin S., Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene. Atherosclerosis. 2022;349:17-35.https://doi.org/10.1016/j.atherosclerosis.2022.04.003.Coassin S., Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene. Atherosclerosis. 2022;349:17-35.https://doi.org/10.1016/j.atherosclerosis.2022.04.003.Lampsas S., Xenou M., Oikonomou E., et al.Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules. 2023;28(3):969. https://doi.org/10.3390/molecules28030969.Lampsas S., Xenou M., Oikonomou E., et al.Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. Molecules. 2023;28(3):969. https://doi.org/10.3390/molecules28030969.Kronenberg F., Mora S., Stroes E.S.G., et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. https://doi.org/10.1093/eurheartj/ehac361.Kronenberg F., Mora S., Stroes E.S.G., et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. https://doi.org/10.1093/eurheartj/ehac361.Naglic D.T., Manojlovic M., Pejakovic S., et al. Lipoprotein(a): Role in atherosclerosis and new treatment options. Biomol Biomed. 2023;23(4):575-583. https://doi.org/10.17305/bb.2023.8992.Naglic D.T., Manojlovic M., Pejakovic S., et al. Lipoprotein(a): Role in atherosclerosis and new treatment options. Biomol Biomed. 2023;23(4):575-583. https://doi.org/10.17305/bb.2023.8992.Ruscica M., Sirtori C.R., Corsini A., et al. Lipoprotein(a): Knowns, unknowns and uncertainties. Pharmacol. Res. 2021;173:105812. https://doi.org/10.1016/j.phrs.2021.105812.Ruscica M., Sirtori C.R., Corsini A., et al. Lipoprotein(a): Knowns, unknowns and uncertainties. Pharmacol. Res. 2021;173:105812. https://doi.org/10.1016/j.phrs.2021.105812.Reyes-Soffer G., Ginsberg H.N., Berglund L., et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60. https://doi.org/10.1161/ATV.0000000000000147.Reyes-Soffer G., Ginsberg H.N., Berglund L., et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-e60. https://doi.org/10.1161/ATV.0000000000000147.Vinci P., Di Girolamo F.G., Panizon E., et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int. J. Environ. Res. Public Health. 2023;20(18):6721. https://doi.org/10.3390/ijerph20186721.Vinci P., Di Girolamo F.G., Panizon E., et al. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. Int. J. Environ. Res. Public Health. 2023;20(18):6721. https://doi.org/10.3390/ijerph20186721.Jawi M.M., Frohlich J., Chan S.Y. Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020;2020:3491764. https://doi.org/10.1155/2020/3491764.Jawi M.M., Frohlich J., Chan S.Y. Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020;2020:3491764. https://doi.org/10.1155/2020/3491764.Ferretti G., Bacchetti T., Johnston T.P., et al. Lipoprotein(a): A missing culprit in the management of athero-thrombosis? J. Cell. Physiol. 2018;233(4):2966-2981. https://doi.org/10.1002/jcp.26050.Ferretti G., Bacchetti T., Johnston T.P., et al. Lipoprotein(a): A missing culprit in the management of athero-thrombosis? J. Cell. Physiol. 2018;233(4):2966-2981. https://doi.org/10.1002/jcp.26050.Mack S., Coassin S., Rueedi R., et al. A genome-wide association meta-analysis on lipoprotein (а) concentrations adjusted for apolipoprotein (а) isoforms. J Lipid Res. 2017;58(9):1834-1844. https://doi.org/10.1194/jlr.M076232.Mack S., Coassin S., Rueedi R., et al. A genome-wide association meta-analysis on lipoprotein (а) concentrations adjusted for apolipoprotein (а) isoforms. J Lipid Res. 2017;58(9):1834-1844. https://doi.org/10.1194/jlr.M076232.Hoekstra M., Chen H.Y., Rong J., et al. Genome-Wide association study highlights APOH as a novel locus for lipoprotein(a) levels-brief report. Arterioscler Thromb Vasc Biol. 2021;41(1):458464. https://doi.org/10.1161/ATVBAHA.120.314965.Hoekstra M., Chen H.Y., Rong J., et al. Genome-Wide association study highlights APOH as a novel locus for lipoprotein(a) levels-brief report. Arterioscler Thromb Vasc Biol. 2021;41(1):458464. https://doi.org/10.1161/ATVBAHA.120.314965.Ugovšek S., Šebeštjen M. Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation. Biomolecules. 2021;12(1):26. https://doi.org/10.3390/biom12010026.Ugovšek S., Šebeštjen M. Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation. Biomolecules. 2021;12(1):26. https://doi.org/10.3390/biom12010026.Després A.A., Perrot N., Poulin A., et al. Lipoprotein(a), oxidized phospholipids, and aortic valve microcalcification assessed by 18F-sodium fluoride positron emission tomography and computed tomography. CJC Open. 2019;1(3):131-40. https://doi.org/10.1016/j.cjco.2019.03.004.Després A.A., Perrot N., Poulin A., et al. Lipoprotein(a), oxidized phospholipids, and aortic valve microcalcification assessed by 18F-sodium fluoride positron emission tomography and computed tomography. CJC Open. 2019;1(3):131-40. https://doi.org/10.1016/j.cjco.2019.03.004.Boffa M.B., Koschinsky M.L. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat. Rev. Cardiol. 2019;16:305-318. https://doi.org/10.1038/s41569-018-0153-2.Boffa M.B., Koschinsky M.L. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat. Rev. Cardiol. 2019;16:305-318. https://doi.org/10.1038/s41569-018-0153-2.Kotani K., Banach M. Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9. J. Thorac. Dis. 2017;9(1):E78-E82. https://doi.org/10.21037/jtd.2017.01.40.Kotani K., Banach M. Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9. J. Thorac. Dis. 2017;9(1):E78-E82. https://doi.org/10.21037/jtd.2017.01.40.Nissen S.E., Wolski K., Cho L., et al. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart. 2022;9(2):e002060. http://doi.org/10.1136/openhrt-2022-002060corr1.Nissen S.E., Wolski K., Cho L., et al. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart. 2022;9(2):e002060. http://doi.org/10.1136/openhrt-2022-002060corr1.Ma G.S., Chiou T.T., Wilkinson M.J. Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes. Curr Cardiol Rep. 2023;25(10):1175-1187. https://doi.org/10.1007%2Fs11886-023-01937-z.Ma G.S., Chiou T.T., Wilkinson M.J. Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes. Curr Cardiol Rep. 2023;25(10):1175-1187. https://doi.org/10.1007%2Fs11886-023-01937-z.Zhang J., Jia L., Yang Y., et al. Lipoprotein (а) and myocardial infarction: impact on long-term mortality. Lipids Health Dis. 2023;22:70. https://doi.org/10.1186%2Fs12944-023-01841-z.Zhang J., Jia L., Yang Y., et al. Lipoprotein (а) and myocardial infarction: impact on long-term mortality. Lipids Health Dis. 2023;22:70. https://doi.org/10.1186%2Fs12944-023-01841-z.Amiri M., Raeisi-Dehkordi H., Verkaar A.J.C.F., et al. Circulating lipoprotein (а)and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis. Eur J. Epidemiol. 2023;38(5):485-499. https://doi.org/10.1007/s10654-022-00956-4.Amiri M., Raeisi-Dehkordi H., Verkaar A.J.C.F., et al. Circulating lipoprotein (а)and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis. Eur J. Epidemiol. 2023;38(5):485-499. https://doi.org/10.1007/s10654-022-00956-4.Hoogeveen R.C., Ballantyne C.M. Residual cardiovascular risk at low LDL: Remnants, lipoprotein(a), and inflammation. Clin. Chem. 2021;67(1):143-153. https://doi.org/10.1093/clinchem/hvaa252.Hoogeveen R.C., Ballantyne C.M. Residual cardiovascular risk at low LDL: Remnants, lipoprotein(a), and inflammation. Clin. Chem. 2021;67(1):143-153. https://doi.org/10.1093/clinchem/hvaa252.Liu T., Yoon W.S., Lee S.R. Recent updates of lipoprotein(a) and cardiovascular disease. ChonnamMed J. 2021;57(1):36-43. https://doi.org/10.4068/cmj.2021.57.1.36.Liu T., Yoon W.S., Lee S.R. Recent updates of lipoprotein(a) and cardiovascular disease. ChonnamMed J. 2021;57(1):36-43. https://doi.org/10.4068/cmj.2021.57.1.36.Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 2018;379(22):2097-107. https://doi.org/10.1056/nejmoa1801174.Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 2018;379(22):2097-107. https://doi.org/10.1056/nejmoa1801174.Sabatine M.S., Giugliano R.P., Keech A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 2017;376(18):1713-22. https://doi.org/10.1056/nejmoa1615664.Sabatine M.S., Giugliano R.P., Keech A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 2017;376(18):1713-22. https://doi.org/10.1056/nejmoa1615664.Jang A.Y., Lim S., Jo S.H., et al. New Trends in Dyslipidemia Treatment. Circ. J. 2021;85(6);759-768. https://doi.org/10.1253/circj.CJ-20-1037.Jang A.Y., Lim S., Jo S.H., et al. New Trends in Dyslipidemia Treatment. Circ. J. 2021;85(6);759-768. https://doi.org/10.1253/circj.CJ-20-1037.Tsimikas S., Karwatowska-Prokopczuk E., Gouni-Berthold I., et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N. Engl. J. Med. 2020;382(3):244-255. https://doi.org/10.1056/nejmoa1905239.Tsimikas S., Karwatowska-Prokopczuk E., Gouni-Berthold I., et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N. Engl. J. Med. 2020;382(3):244-255. https://doi.org/10.1056/nejmoa1905239.Yeang C., Karwatowska-Prokopczuk E., Su F., et al. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. J. Am. Coll. Cardiol. 2022;79(11):1035-1046. https://doi.org/10.1016/j.jacc.2021.12.032.Yeang C., Karwatowska-Prokopczuk E., Su F., et al. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. J. Am. Coll. Cardiol. 2022;79(11):1035-1046. https://doi.org/10.1016/j.jacc.2021.12.032.Berk K.A., Borgeraas H., Narverud I., et al. Differential effects of bariatric surgery and lifestyle interventions on plasma levels of Lp(a) and fatty acids. Lipids Health Dis. 2022;21:145. https://doi.org/10.1186/s12944-022-01756-1.Berk K.A., Borgeraas H., Narverud I., et al. Differential effects of bariatric surgery and lifestyle interventions on plasma levels of Lp(a) and fatty acids. Lipids Health Dis. 2022;21:145. https://doi.org/10.1186/s12944-022-01756-1.Schwartz G.G., Ballantyne C.M., Barter P.J., et al. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018;3(2):164-168. https://doi.org/10.1001/jamacardio.2017.3833.Schwartz G.G., Ballantyne C.M., Barter P.J., et al. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. Analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018;3(2):164-168. https://doi.org/10.1001/jamacardio.2017.3833.

The authors declare that there are no conflicts of interest present.